Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : the Women of SI -- Ignore unavailable to you. Want to Upgrade?

To: Rainy_Day_Woman who wrote (713)	4/12/1999 10:27:00 AM
From: Volsi Mimir	Read Replies (1) \| Respond to of 1691

are you guys only into BIG cap issues or is this relevant: NeoPath Learns of Policy Decision From the California Department of Health Services to Reimburse for AutoPap Primary Pap Smear Screening California State Medi-Cal Program Provides Health Benefits for 5 Million Residents REDMOND, Wash--(BUSINESS WIRE)--April 12, 1999-- NeoPath, Inc. (Nasdaq:NPTH - news) today announced that California's Medicaid program, Medi-Cal, will offer reimbursement for the AutoPap® Primary Pap Smear Screening System as a new Medi-Cal benefit. Medi-Cal's computerized claim-processing system will be able to accept claims for AutoPap primary screening of Pap smears effective June 28, 1999, and it is anticipated that reimbursement coverage will be retroactive. California's Medi-Cal program is one of the largest Medicaid programs in the U.S., serving approximately 5 million residents of that State. ''The decision by the California Department of Health Services to reimburse the AutoPap System is an affirmation of AutoPap's superior cost-effectiveness in early detection of cervical cancer,'' said Ronald R. Bromfield, president and CEO of NeoPath, ''and we believe California may lead other state Medicaid programs to reimburse for AutoPap. NeoPath's proprietary technology applied to the evaluation of Pap smear slides in the AutoPap Primary Screening System not only helps save women's lives, but also improves operational efficiencies in the fight against cervical cancer.'' neopath: neopath.com neopath on sleuth: companysleuth.com [2 newer patients] NeoPath's innovative technologies have resulted in more than 20 United States patents issued or allowed and numerous patents pending. The company also has applied for patent protection in Japan, Canada, Australia and Europe. [stock bottomed out] sherry- dont have to answer-- i understand. if this helps women- i would like to know-- all the threads are dead.... i bought at 3 15/16 - bottom fishin no hype-- anyone know how important or how big is neopath compared to other companies who provide? SI thread to NPTH: Subject 13915 Please do your own DD! eddy